339 related articles for article (PubMed ID: 33937401)
1. Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of
Yang L; Zou A; Wu H; Guo H; Zhang F; Zou B; Wang J
Biomed Res Int; 2021; 2021():6150628. PubMed ID: 33937401
[TBL] [Abstract][Full Text] [Related]
2. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
Lin K; Huang L; Wang Y; Li K; Ye Y; Yang S; Li A
Helicobacter; 2023 Dec; 28(6):e13015. PubMed ID: 37634236
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
Papastergiou V; Georgopoulos SD; Karatapanis S
World J Gastroenterol; 2014 Aug; 20(29):9898-911. PubMed ID: 25110420
[TBL] [Abstract][Full Text] [Related]
5. Importance of antimicrobial susceptibility testing for the management of eradication in
Arslan N; Yılmaz Ö; Demiray-Gürbüz E
World J Gastroenterol; 2017 Apr; 23(16):2854-2869. PubMed ID: 28522904
[TBL] [Abstract][Full Text] [Related]
6. Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success.
Zambon CF; Fasolo M; Basso D; D'Odorico A; Stranges A; Navaglia F; Fogar P; Greco E; Schiavon S; Padoan A; Fadi E; Sturniolo GC; Plebani M; Pedrazzoli S
J Gastrointest Surg; 2007 Nov; 11(11):1506-14; discussion 1514. PubMed ID: 17846855
[TBL] [Abstract][Full Text] [Related]
7. High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.
Zhang M
World J Gastroenterol; 2015 Dec; 21(48):13432-7. PubMed ID: 26730153
[TBL] [Abstract][Full Text] [Related]
8. Seven-day genotypic resistance-guided triple
Papastergiou V; Mathou N; Licousi S; Evgenidi A; Paraskeva KD; Giannakopoulos A; Stavrou PZ; Platsouka E; Karagiannis JA
Ann Gastroenterol; 2018; 31(2):198-204. PubMed ID: 29507466
[TBL] [Abstract][Full Text] [Related]
9. Role of MIC levels and 23S rRNA mutation sites to clarithromycin in 14-day clarithromycin bismuth quadruple therapy for
Chen Y; Li S; Li W; Wang Y; Shi J; Xu X; Zhang P; Chen D; Gang R; Luo Q
Heliyon; 2024 Apr; 10(8):e29774. PubMed ID: 38699713
[TBL] [Abstract][Full Text] [Related]
10. Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review.
Wu X; Duan M; Kong Q; Zeng S; Xu L; Li Y; Yang X; Zuo X
Helicobacter; 2024; 29(1):e13048. PubMed ID: 38716864
[TBL] [Abstract][Full Text] [Related]
11. Culture-based susceptibility-guided tailored versus empirical concomitant therapy as first-line Helicobacter pylori treatment: A randomized clinical trial.
Lee JH; Min BH; Gong EJ; Kim JY; Na HK; Ahn JY; Kim DH; Choi KD; Min YW; Lee H; Lee JH; Jung HY; Kim JJ
United European Gastroenterol J; 2024 Jun; ():. PubMed ID: 38887840
[TBL] [Abstract][Full Text] [Related]
12. Biofilm Formation by Helicobacter pylori and Its Involvement for Antibiotic Resistance.
Yonezawa H; Osaki T; Kamiya S
Biomed Res Int; 2015; 2015():914791. PubMed ID: 26078970
[TBL] [Abstract][Full Text] [Related]
13. Study on the value of antibiotic-resistant gene detection in
Dai J; Zhao J; Mao L; Hu Y; Lv B
Exp Ther Med; 2022 Mar; 23(3):228. PubMed ID: 35222705
[TBL] [Abstract][Full Text] [Related]
14. The effects and mechanisms of natural products on
Deng R; Chen X; Zhao S; Zhang Q; Shi Y
Front Cell Infect Microbiol; 2024; 14():1360852. PubMed ID: 38481665
[No Abstract] [Full Text] [Related]
15. Current paradigms in the management of refractory Helicobacter pylori infection.
Jearth V; Panigrahi MK
Indian J Gastroenterol; 2023 Dec; 42(6):766-779. PubMed ID: 37737326
[TBL] [Abstract][Full Text] [Related]
16. Lactic acid bacterial extracts as anti-Helicobacter pylori: a molecular approach.
El-Adawi H; El-Sheekh M; Khalil M; El-Deeb N; Hussein M
Ir J Med Sci; 2013 Sep; 182(3):439-52. PubMed ID: 23404362
[TBL] [Abstract][Full Text] [Related]
17. Novel MAXPOWER biological antibacterial liquid for eradicating oral Helicobacter pylori.
Lai Y; Dong X; Song Y; Zhao J; Du Y; Li Z
BMC Infect Dis; 2024 May; 24(1):540. PubMed ID: 38811871
[TBL] [Abstract][Full Text] [Related]
18. Association between Helicobacter pylori infection, eradication and diabetes mellitus.
Kato M; Toda A; Yamamoto-Honda R; Arase Y; Sone H
J Diabetes Investig; 2019 Sep; 10(5):1341-1346. PubMed ID: 30663265
[TBL] [Abstract][Full Text] [Related]
19. Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in
Domanovich-Asor T; Motro Y; Khalfin B; Craddock HA; Peretz A; Moran-Gilad J
Microorganisms; 2020 Dec; 9(1):. PubMed ID: 33374988
[TBL] [Abstract][Full Text] [Related]
20. Empirical or susceptibility-guided treatment for
Gisbert JP
Therap Adv Gastroenterol; 2020; 13():1756284820968736. PubMed ID: 33240392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
